These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 33610731)

  • 41. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
    Hernandez I; Maddison LA; Wei Y; DeMayo F; Petras T; Li B; Gingrich JR; Rosen JM; Greenberg NM
    Mol Cancer Res; 2003 Dec; 1(14):1036-47. PubMed ID: 14707287
    [TBL] [Abstract][Full Text] [Related]  

  • 42. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polyethylenimines for siRNA and miRNA delivery in vivo.
    Höbel S; Aigner A
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2013; 5(5):484-501. PubMed ID: 23720168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting the KRAS, p38α, and NF-κB in lung adenocarcinoma cancer cells: The effect of combining RNA interferences with a chemical inhibitor.
    Zarredar H; Pashapour S; Farajnia S; Ansarin K; Baradaran B; Ahmadzadeh V; Safari F
    J Cell Biochem; 2019 Jun; 120(6):10670-10677. PubMed ID: 30656741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Method for Targeted Nonviral siRNA Delivery in Cancer and Inflammatory Diseases.
    Kandil R; Xie Y; Mehta A; Merkel O
    Methods Mol Biol; 2020; 2059():155-166. PubMed ID: 31435920
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression.
    Shang A; Gu C; Zhou C; Yang Y; Chen C; Zeng B; Wu J; Lu W; Wang W; Sun Z; Li D
    Cell Commun Signal; 2020 Mar; 18(1):52. PubMed ID: 32228650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A homologous promoterless K-ras cDNA targeting endogenous K-ras expression inhibits human pancreatic cancer cell growth in vitro and in vivo.
    Ren XY; Liang ZY; Shi XH; Liu TH
    Cancer Biol Ther; 2008 Oct; 7(10):1641-7. PubMed ID: 18769120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exosome-mediated delivery of siRNA in vitro and in vivo.
    El-Andaloussi S; Lee Y; Lakhal-Littleton S; Li J; Seow Y; Gardiner C; Alvarez-Erviti L; Sargent IL; Wood MJ
    Nat Protoc; 2012 Dec; 7(12):2112-26. PubMed ID: 23154783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
    Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
    Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exosomes: Natural Carriers for siRNA Delivery.
    Kumar L; Verma S; Vaidya B; Gupta V
    Curr Pharm Des; 2015; 21(31):4556-65. PubMed ID: 26486142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells.
    Zhang Z; Jiang G; Yang F; Wang J
    Cancer Biol Ther; 2006 Nov; 5(11):1481-6. PubMed ID: 17172815
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers.
    Maheshwari R; Tekade M; Gondaliya P; Kalia K; D'Emanuele A; Tekade RK
    Nanomedicine (Lond); 2017 Nov; 12(21):2653-2675. PubMed ID: 28960165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases.
    Kedinger V; Meulle A; Zounib O; Bonnet ME; Gossart JB; Benoit E; Messmer M; Shankaranarayanan P; Behr JP; Erbacher P; Bolcato-Bellemin AL
    BMC Cancer; 2013 Jul; 13():338. PubMed ID: 23835136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy.
    Xu L; Pirollo KF; Chang EH
    J Control Release; 2001 Jul; 74(1-3):115-28. PubMed ID: 11489488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
    Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
    J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanoparticulate RNA delivery systems in cancer.
    Sharma A; Jha NK; Dahiya K; Singh VK; Chaurasiya K; Jha AN; Jha SK; Mishra PC; Dholpuria S; Astya R; Nand P; Kumar A; Ruokolainen J; Kesari KK
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1271. PubMed ID: 32729987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
    Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
    Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
    Luan X; Rahme K; Cong Z; Wang L; Zou Y; He Y; Yang H; Holmes JD; O'Driscoll CM; Guo J
    Eur J Pharm Biopharm; 2019 Apr; 137():56-67. PubMed ID: 30779980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex.
    Nguyen DM; Wiehle SA; Koch PE; Branch C; Yen N; Roth JA; Cristiano RJ
    Cancer Gene Ther; 1997; 4(3):191-8. PubMed ID: 9171938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.